Seizures and Anti-Epileptic Drugs in Neuro-Oncology

  • Michael J. Glantz
  • Julia Batten


Seizures are common in patients with central nervous system cancer, although the exact frequency of seizures depends considerably on the location, growth rate, and histology of the tumor. The occurrence of a first seizure in an adult mandates a neuroimaging study of the brain, preferably an enhanced MRI scan with FLAIR sequences. Focal seizures in children, particularly in the presence of post-ictal or intra-ictal deficits, may also merit a similar evaluation. In patients with known cancer, an MRI scan with FLAIR images and contrast enhancement is the optimum neuroimaging test. Extensive studies to evaluate infectious, metabolic, and drug-related etiologies are also critical, and in many cases a cerebrospinal fluid examination is indicated. While surgical therapy of tumorassociated seizures holds promise, particularly for patients with low-grade primary brain tumors, intraoperative electrocorticography may be required for optimum seizure control, and post-operative anticonvulsant medication is usually necessary. Anticonvulsant medications are associated with more frequent and often more severe side effects in patients with cancer than in patients with other causes for their seizures. These side effects include important interactions with corticosteroids and chemotherapeutic agents, and should influence the choice of anticonvulsant agents and the monitoring schedule of patients under treatment. Prophylactic anticonvulsants are not effective, and should not be used routinely.

Key Words

seizure epilepsy anticonvulsant therapy brain tumors brain metastases anticonvulsant prophylaxis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Prados MD, Berger MS, Wilson CB. Primary central nervous system tumors: Advances in knowledge and treatment. CA Cancer J Clin 1998;48:331–360.PubMedGoogle Scholar
  2. 2.
    Posner JB. Neurologic Complications of Cancer. Philadelphia: F.A. Davis Company, 1995.Google Scholar
  3. 3.
    CBTRUS (2005). Statistical report: primary brain tumors in the United States, 1998–2002. Published by the Central Brain Tumor Registry of the United States, 2006.Google Scholar
  4. 4.
    Barnholtz-Sloan JS, Sloan AE, Davis FG et al. Incidence proportions of brain metastases in patients diagnosed (1973–2001) in the metropolitan Detroit cancer surveillance system. J Clin Oncol 2004;22:2865–2872.PubMedGoogle Scholar
  5. 5.
    Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.PubMedGoogle Scholar
  6. 6.
    Hildebrand J, Lecaille C, Perennes J et al. Epileptic seizures during follow-up of patients treated for primary brain tumors. Neurology 2005;65:212–215.PubMedGoogle Scholar
  7. 7.
    Chang SM, Parney IF, Huang W et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005;293:557–564.PubMedGoogle Scholar
  8. 8.
    Forsyth PA, Weaver S, Fulton D et al. Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci 2003;30:89–90.Google Scholar
  9. 9.
    Glantz MJ, Cole BF, Friedberg MH et al. A randomized, blinded, placebo-controlled trial of divalproex sodium prophylaxis in adults with newly diagnosed brain tumors. Neurology 1996;46:985–991.PubMedGoogle Scholar
  10. 10.
    Dent S, Bociek G. Prophylactic anticonvulsants for cancer patients with newly diagnosed brain metastases. Proc Am Soc Clin Oncol 1996;15:529, 1996 [abstract].Google Scholar
  11. 11.
    Moots PL, Maciunas RJ, Eisert DR et al. The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995;52:717–724.PubMedGoogle Scholar
  12. 12.
    Hung S, Hilsenbeck S, Feun L. Seizure prophylaxis with phenytoin in patients with brain metastases. Proc Am Soc Clin Oncol 10:A1151, 1991 [abstract].Google Scholar
  13. 13.
    Franceschetti S, Binelli S, Casazza M et al. Influence of surgery and antiepileptic drugs on seizures symptomatic of cerebral tumours. Acta Neurochirurgica 1990;103:47–51.PubMedGoogle Scholar
  14. 14.
    Hagen NA, Cirrincione C, Thaler HT et al. The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology 1990;40:158–160.PubMedGoogle Scholar
  15. 15.
    Cohen N, Strauss G, Lew R et al. Should prophylactic anticonvulsant be administered to patients with newly diagnosed cerebral metastases? A retrospective analysis. J Clin Oncol 1988;6:1621–1624.PubMedGoogle Scholar
  16. 16.
    Gilbert MR, Grossman SA. Incidence and nature of neurologic problems in patients with solid tumors. Am J Med 1986;81:951–954.PubMedGoogle Scholar
  17. 17.
    Boarini DJ, Beck DW, VanGilder JC. Post-operative prophylactic anticonvulsant therapy in cerebral gliomas. Neurosurgery 1985;16:290–292.PubMedGoogle Scholar
  18. 18.
    North JB, Penhall RK, Hanieh A et al. Phenytoin and postoperative epilepsy: a double-blind study. J Neurosurg 1983;58:672–677.PubMedGoogle Scholar
  19. 19.
    Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol 1983;1:313–317.PubMedGoogle Scholar
  20. 20.
    Mahaley MS, Dudka L. The role of anticonvulsant medications in the management of patients with anaplastic gliomas. Surg Neurol 1981;16:399–401.PubMedGoogle Scholar
  21. 21.
    Zimm S, Wampler GL, Stablein D et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981;48:384–394.PubMedGoogle Scholar
  22. 22.
    Cobb JL, Lekos A, Cole BF et al. Natural history of seizures and the role of anticonvulsants in patients with primary and metastatic central nervous system cancer. Neurology 1997;48:A19 [abstract].Google Scholar
  23. 23.
    Olson JD, Riedel E, DeAngelis LM. Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology. 2000;54:1442–1448.PubMedGoogle Scholar
  24. 24.
    Daumas-Duport C. Dysembryoplastic neuroepithelial tumours. Brain Pathol 1993;3:283–295.PubMedGoogle Scholar
  25. 25.
    Gilles FH, Sobell E, Leviton A et al. Epidemiology of seizures in children with brain tumors. J Neurooncol 1992;12:53–68.PubMedGoogle Scholar
  26. 26.
    Daumas-Duport C, Scheithauer BW, Chodkiewicz JP et al. Dysembryoplastic neuroepithelial tumor: a surgically curable tumor of young patents with intractable partial seizures: report of thirty-nine cases. Neurosurgery 1988;23:545–556.PubMedGoogle Scholar
  27. 27.
    Mathieson G. Pathologic aspects of epilepsy with special reference to the surgical pathology of focal cerebral seizures. Adv Neurol 1975;8:107–138.PubMedGoogle Scholar
  28. 28.
    Rasmussen T. Cortical resection in the treatment of focal epilepsy. Adv Neurol 1975;8:139–154.PubMedGoogle Scholar
  29. 29.
    Rasmussen T. Surgery of epilepsy associated with brain tumors. Adv Neurol 1975;8:227–239.PubMedGoogle Scholar
  30. 30.
    Backus RE, Millichap JG. The seizure as a manifestation of intracranial tumor in childhood. Pediatrics 1962;29:978.PubMedGoogle Scholar
  31. 31.
    Penfield W, Erickson TC, Tarlov I. Relation of intracranial tumors and symptomatic epilepsy. Arch Neurol Psychiatr 1940;44:300–315.Google Scholar
  32. 32.
    Iannelli A, Guzzetta F, Battaglia D et al. Surgical treatment of temporal tumors associated with epilepsy in children. Pediatr Neurosurg 2000 32:248–254.PubMedGoogle Scholar
  33. 33.
    Hirsch JF, Saint Rose C, Pierre-Kahn A et al. Benign astrocytic and oligodendrocytic tumors of the cerebral hemispheres in children. J Neurosurg 1989;70:568–572.PubMedGoogle Scholar
  34. 34.
    Janszky J, Jokeit H, Schulz R et al. EEG predicts surgical outcome in lesional frontal lobe epilepsy. Neurology 2000;54:1470–1476.PubMedGoogle Scholar
  35. 35.
    Diehl B, Luders HO. Temporal lobe epilepsy: when are invasive recordings needed? Epilepsia 2000;41 Suppl 3:S61–S74.PubMedGoogle Scholar
  36. 36.
    Zentner J, Hufnagel A, Wolf HK et al. Surgical treatment of temporal lobe epilepsy: clinical, radiological, and histopathological findings in 178 patients. J Neurol Neurosurg Psychiatr 1995;58:666–673.PubMedGoogle Scholar
  37. 37.
    Plate KH, Wieser HG, Yasargil MG et al. Neuropathologic finding in 224 patients with temporal lobe epilepsy. Acta Neuropathol 1993;86:433–438.PubMedGoogle Scholar
  38. 38.
    Wolf HK, Campos MG, Zentner J et al. Surgical pathology of temporal lobe epilepsy.: experience with 216 cases. J Neuropathol Exp Neurol 1993;52:499–506.PubMedGoogle Scholar
  39. 39.
    Frater JL, Prayson RA, Morris III HH et al. Surgical pathologic findings of extratemporal-based intractable epilepsy: a study of 133 consecutive resections. Arch Pathol Lab Med 2000;124:545–549.PubMedGoogle Scholar
  40. 40.
    Jacobs M, Phuphanich S. Seizures in brain metastasis and meningeal carcinomatosis. Proc Am Soc Clin Oncol 1990;9:96 [abstract].Google Scholar
  41. 41.
    Olson ME, Chernik NL, Posner JB. Infiltration of the leptomeninges by systemic cancer: a clinical and pathologic study. Arch Neurol 1974;30:122–137.PubMedGoogle Scholar
  42. 42.
    Wasserstrom WR, Schwartz MK, Fleisher M et al. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982;49:759–772.PubMedGoogle Scholar
  43. 43.
    Smith DF, Hutton JL, Sandermann D et al. The prognosis of primary intracerebral tumours presenting with epilepsy: the outcome of medical and surgical management. J Neurol Neurosurg Psychiatr 1991;54:915–920.PubMedGoogle Scholar
  44. 44.
    Penfield W, Jasper H. Epilepsy and the Functional Anatomy of the Human Brain. Little, Brown & Company, Boston, MA, 1954.Google Scholar
  45. 45.
    White JC, Liu CT, Mixter WJ. Focal epilepsy: a statistical study of its causes and the results of surgical treatment. I. Epilepsy secondary to intracranial tumors. N Engl J Med 1948;438:891–899.Google Scholar
  46. 46.
    Suarez JC, Sfaello ZM, Guerrero A et al. Epilepsy and brain tumors in infancy and adolescence. Child’s Nerv Syst 1986;2:169–174.Google Scholar
  47. 47.
    Blume WT, Girvin JP, Kaufmann JC. Childhood brain tumors presenting as chronic uncontrolled seizure disorders. Ann Neurol 1982;12:538–541.PubMedGoogle Scholar
  48. 48.
    Hirtz D, Ashwal S, Berg A et al. Practice parameter: evaluating a first nonfebrile seizure in children: report of the quality standards subcommittee of the American Academy of Neurology, The Child Neurology Society, and The American Epilepsy Society. Neurology. 2000;55:616–23.PubMedGoogle Scholar
  49. 49.
    Commission on Neuroimaging of the International League Against Epilepsy. Recommendations for neuroimaging of patients with epilepsy. Epilepsia 1997;38:1255–1256.Google Scholar
  50. 50.
    Schoenenberger RA, Heim SM. Indication for computed tomography of the brain in patients with first uncomplicated generalized seizure. BMJ 1994;309:986–989.PubMedGoogle Scholar
  51. 51.
    Hopkins A, Garman A, Clarke C. The first seizure in adult life: value of clinical features, electroencephalography, and computerized tomgraphic scanning in prediction of seizure recurrence. Lancet 1988;1:721–726.PubMedGoogle Scholar
  52. 52.
    Daras M, Tuchman AJ, Strobos RJ. Computed tomography in adult-onset epileptic seizures in a city hospital population. Epilepsia. 1987 Sep–Oct;28:519–522.Google Scholar
  53. 53.
    Ramirez-Lassepas M, Cipolle RJ, Morillo LR et al. Value of computed tomographic scan in the evaluation of adult patients after their first seizure. Ann Neurol 1984;15:536–543.PubMedGoogle Scholar
  54. 54.
    Russo LS, Goldstein KH. The diagnostic assessment of single seizures: is cranial computed tomography necessary? Arch Neurol 1983;40:744–746.PubMedGoogle Scholar
  55. 55.
    Bradley WG, Shey RB. MR imaging evaluation of seizures. Radiology 2000;214:651–656.PubMedGoogle Scholar
  56. 56.
    Taillibert S, Oppenheim C, Baulac M et al. Yield of fluid-attenuated inversion recovery in drug-resistant focal epilepsy with noninformative conventional magnetic resonance imaging. Eur Neurol 1999;41:64–72.PubMedGoogle Scholar
  57. 57.
    Bergin PS, Fish DR, Shorvon SD et al. Magnetic resonance imaging in partial epilepsy: additional abnormalities shown with the fluid attenuated inversion recovery (FLAIR) pulse sequence. J Neurol Neurosurg Psychiatry 1995;58:439–443.PubMedGoogle Scholar
  58. 58.
    Fried I, Kim JH, Spencer DD. Limbic and neocortical gliomas associated with intractable seizures: A distinct clinicopathological group. Neurosurgery 1994;34:815–824.PubMedGoogle Scholar
  59. 59.
    Recht LD, Smith TW, Lew RA. Suspected low-grade glioma: how safe is deferring treatment? Ann Neurol 1992;31:431–436.PubMedGoogle Scholar
  60. 60.
    Arseni C, Maretsis M. Focal epileptic seizures ipsilateral to the tumour. Acta Neurochir 1979;49:47–60.Google Scholar
  61. 61.
    Howe JG, Gibbon JD. Uncinate seizures and tumors, a myth reexamined. Ann Neurol. 1982;12:227.PubMedGoogle Scholar
  62. 62.
    Lund M. Epilepsy in association with intracranial tumour. Acta Psychiatr 1952;81(suppl).Google Scholar
  63. 63.
    Meyer JS, Portnoy HD. Post-epileptic paralysis.: a clinical and experimental study. Brain 1959;82(part II):162–185.Google Scholar
  64. 64.
    Cornford EM. Epilepsy and the blood–brain barrier: endothelial cell responses to seizures. Adv Neurol 1999;79:845–862.PubMedGoogle Scholar
  65. 65.
    Nitsch C, Klatzo J. Regional patterns of blood–brain barrier breakdown during epileptiform seizures induced by various convulsive agents. J Neurol Sci 1983;59:305–322.PubMedGoogle Scholar
  66. 66.
    Glantz MJ, Cole BF, Glantz LK et al. Cerebrospinal fluid cytology in patients with cancer: how to minimize false negative results. Cancer 1998;82:733–739.PubMedGoogle Scholar
  67. 67.
    Cross NE, Glantz MJ. Neurologic complications of radiation therapy. In: Wen PY, Glantz MJ, eds. Complications of Systemic Cancer. W.B. Saunders Co., Philadelphia, 2003, pp. 249–277.Google Scholar
  68. 68.
    Gultekin SH, Rosenfeld MR, Voltz R et al. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 2000;123 (Pt 7):1481–1494.PubMedGoogle Scholar
  69. 69.
    Lehmann DF, Hurteau TE, Newman N et al. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Therapeutics 1997;62:225–229.Google Scholar
  70. 70.
    Sirven JI, Wingerchuk DM, Drazkowski JF et al. Seizure prophylaxis in patients with brain tumors: a metaanalysis. Mayo Clin Proc 2004;79:1489–1494.PubMedGoogle Scholar
  71. 71.
    Taphoorn MJ. Neurocognitive sequelae in the treatment of low-grade gliomas. Semin Oncol 2003;(6 suppl 19):45–48.Google Scholar
  72. 72.
    Ahmed I, Reichenberg J, Lucas A et al. Erythema multiforme associated with phenytoin and cranial radiation therapy: a report of three patients and review of the literature. Int J Dermatol 2004;43:67–73.PubMedGoogle Scholar
  73. 73.
    Cockey GH, Amann ST, Reents SB et al. Stevens–Johnson syndrome resulting from whole-brain radiation and phenytoin. Am J Clin Oncol 1996;19:32–34.PubMedGoogle Scholar
  74. 74.
    Borg MF, Probert JC, Zwi LJ. Is phenytoin contraindicated in patients receiving cranial irradiation? Australasian Radiol 1995;39:42–46.Google Scholar
  75. 75.
    Khe HX, Delattre JY, Poisson M. Stevens–Johnson syndrome in a patient receiving cranial irradiation and carbamazepine. Neurology 1990;40:1144–1145.Google Scholar
  76. 76.
    Taylor LP, Posner JB: Phenobarbital rheumatism in patients with brain tumor. Ann Neurol 1989;25:92–94.PubMedGoogle Scholar
  77. 77.
    Delattre J, Safai B, Posner JB. Erythema multiforme and Stevens–Johnson syndrome in patients receiving cranial irradiation and phenytoin. Neurology 38:194–198, 1988.PubMedGoogle Scholar
  78. 78.
    Crawford P. An audit of topiramate use in a general neurology clinic. Seizure 1998;7:207–211.PubMedGoogle Scholar
  79. 79.
    Taylor LP, Posner JB. Phenobarbital rheumatism in patients with brain tumor. Ann Neurol 1989;25:92–94.PubMedGoogle Scholar
  80. 80.
    Sasso E, Delsoldato S, Negrotti A et al. Reversible valproate-induced extrapyramidal disorders. Epilepsia 1994;35:391–393.PubMedGoogle Scholar
  81. 81.
    Sackellares JC, Lee SI, Dreifuss FE. Stupor following administration of valproic acid to patients receiving other antiepileptic drugs. Epilepsia 1979;20:697–703.PubMedGoogle Scholar
  82. 82.
    Kikuchi K, McCormick CI, Neuwelt EA. Immunosuppression by phenytoin: implications for altered immune competence in brain tumor patients. J Neurosurg 61:1085–1090, 1984.PubMedGoogle Scholar
  83. 83.
    Bardana EJ, Gabourel JD, Davies GH et al: Effects of phenytoin on man’s immunity: evaluation of changes in serum immunoglobulins, complement, and anti-nuclear antibody. Am J Med 74:289–296, 1983.PubMedGoogle Scholar
  84. 84.
    Neuwelt EA, Kikuchi K, Hill S et al. Immune responses in patients with brain tumors. Factors such as anti-convulsants that may contribute to impaired cell-mediated immunity. Cancer 51:248–255, 1983.PubMedGoogle Scholar
  85. 85.
    Sorrell TC, Forbes IJ. Depression of immune competence by phenytoin and carbamazepine: studies in vivo and in vitro. Clin Exp Immunol 1975;20:273–285.PubMedGoogle Scholar
  86. 86.
    Dropcho EJ, Soong S. Steroid-induced weakness in patients with primary brain tumors. Neurology 41:1235–1239, 1991.PubMedGoogle Scholar
  87. 87.
    Chalk JB, Ridgeway K, Brophy T et al. Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients. J Neurol Neursurg Psychiatry 1984;47:187–190.Google Scholar
  88. 88.
    Gambertoglio JG, Holford NH, Kapusnik JE, et al. Disposition of total unbound prednisolone in renal transplant patients receiving anticonvulsants. Kidney Int 25:119–123, 1984.PubMedGoogle Scholar
  89. 89.
    Wassner SJ, Malekzadem MH, Pennisi AJ et al. Allograft survival in patients receiving anticonvulsant medications. Clin Nephrol 8:293–297, 1977.PubMedGoogle Scholar
  90. 90.
    Haque N, Thrasher K, Werk E. Studies on dexamethasone metabolism in man: effect of diphenylhydantoin. J Clin Endocrinol Metab 34:44–50, 1972.PubMedGoogle Scholar
  91. 91.
    Gilbert MR, Supko JG, Batchelor T et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 2003;9:2940–2949.PubMedGoogle Scholar
  92. 92.
    Chang SM, Kuhn JG, Rizzo J et al. Phase I study of paclitaxel in patients with recurrent malignant gliomas: a North American Brain Tumor Consortium report. J Clin Oncol 16:2188–2194, 1998.PubMedGoogle Scholar
  93. 93.
    Friedman AH, Ashley DM, Kerby T et al. Topotecan treatment of adults with primary malignant glioma. Proc Am Soc Clin Oncol 17:390a, 1998 [abstract].Google Scholar
  94. 94.
    Grossman SA, Hochberg F, Fisher J et al. Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. Cancer Chemother Pharmacol 42:118–126, 1998.PubMedGoogle Scholar
  95. 95.
    Fetell MR, Grossman SA, Fisher JD et al. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J Clin Oncol 15:3121–3128, 1997.PubMedGoogle Scholar
  96. 96.
    Chang TK, Chen G, Waxman DJ. Modulation of thiotepa antitumor activity in vivo by alteration of liver cytochrome P450-catalyzed drug metabolism. J Pharmacol Exp Therapeutics 274:270–275, 1995.Google Scholar
  97. 97.
    Baker DK, Relling MV, Pui C-H et al. Increased teniposide clearance with concomitant anticonvulsant therapy. J Clin Oncol 10:311–315, 1992.PubMedGoogle Scholar
  98. 98.
    Fitzsimmons WE, Ghalie R, Kaizer H. The effect of hepatic enzyme inducers on busulfan neurotoxicity. Cancer Chemother Pharmacol 27:226–228, 1990.PubMedGoogle Scholar
  99. 99.
    Workman P, Bleehen NM, Wiltshire CR. Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity. Br J Cancer 41:302–304, 1980.PubMedGoogle Scholar
  100. 100.
    Muller PJ, Tator CH, Bloom M. The effect of phenobarbital on the toxicity and tumoricidal activity of CCNU in a murine brain tumor model. J Neurosurg 52:359–366, 1980.PubMedGoogle Scholar
  101. 101.
    Levin VA, Stearns J, Byrd A et al. The effect of phenobarbital pretreatment on the antitumor activity of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), 1-(2–chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 1-(2-chlorethyl)-3-(2,6-dioxo-3-piperidyl-1-nitrosourea (PCNU), on the plasma pharmacokinetics and biotransformation of BCNU. J Pharmacol Exp Ther 208:1–6, 1979.PubMedGoogle Scholar
  102. 102.
    Warren RD, Bender AR. Drug interactions with antineoplastic agents. Cancer Treat Rep 61:1231–1241, 1977.PubMedGoogle Scholar
  103. 103.
    Reich SD, Bachur NR. Alterations in adriamycin efficacy by phenobarbital. Cancer Res 36:3803–3806, 1976.PubMedGoogle Scholar
  104. 104.
    Glantz MJ, Kim L, Choy H, Akerley W. Concurrent chemotherapy and radiotherapy in patients with brain tumors. Oncology 1999;13:78–82.PubMedGoogle Scholar
  105. 105.
    Oberndorfer S, Piribauer M, Marosi C et al. P450 enzyme inducing and nonenzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy. J Neurooncol 2005;72:255–260.PubMedGoogle Scholar
  106. 106.
    Relling MV, Pui C–H, Sandlund JT et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 2000;356:285–290.Google Scholar
  107. 107.
    Jaeckle KA, Ballman K, Uhm J et al. Comparison of survival endpoints in glioblastoma patients receiving or not receiving enzyme-inducing anticonvulsants in NCCTG Trials. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004: 1525.Google Scholar
  108. 108.
    Gattis WA, May DB. Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Ann Pharmacotherapy 30:520–526, 1996.Google Scholar
  109. 109.
    Rabinowicz AL, Hinton DR, Dyck P et al. High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 36:513–515, 1995.PubMedGoogle Scholar
  110. 110.
    Ghosh C, Lazarus HM, Hewlett JS et al. Fluctuation of serum phenytoin concentrations during autologous bone marrow transplant for primary central nervous system tumors. J Neuro-Oncology 12:25–32, 1992.Google Scholar
  111. 111.
    Lackner TE: Interaction of dexamethasone with phenytoin. Pharmacotherapy 11:344–347, 1991.PubMedGoogle Scholar
  112. 112.
    Grossman SA, Sheilder VR, Gilbert MR: Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 87:505–510, 1989.PubMedGoogle Scholar
  113. 113.
    Jarosinski PF, Moslow JA, Alexander MS et al. Altered phenytoin clearance during intensive treatment for acute lymphoblastic leukemia. J Pediatr 112:996–999, 1988.PubMedGoogle Scholar
  114. 114.
    Neef C, Voogd–van der Straaten I. An interaction between cytostatic and anticonvulsant drugs. Clin Pharmacol Ther 43:372–375, 1988.Google Scholar
  115. 115.
    Sylvester RK, Lewis FB, Caldwell KC et al: Impaired phenytoin bioavailability secondary to cisplatinum, vinblastine and bleomycin. Ther Drug Monit 6:302–305, 1984.PubMedGoogle Scholar
  116. 116.
    Perucca E: Pharmacokinetic interactions with antiepileptic drugs. Clin Pharmacokinet 7:57–84, 1982.PubMedGoogle Scholar
  117. 117.
    Finchum RW, Schottelius DD: Decreased phenytoin levels in antineoplastic therapy. Ther Drug Monit 1:277–283, 1979.Google Scholar
  118. 118.
    Dofferhoff ASM, Berendsen HH, Naalt J et al. Decreased phenytoin level after carboplatin treatment. Am J Med 1990;89:247–248.PubMedGoogle Scholar
  119. 119.
    Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology 2006;76(suppl 4):S10–S13.Google Scholar
  120. 120.
    Newton HB. J Neurooncol 78:99–102, 2006PubMedGoogle Scholar
  121. 121.
    White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999;40(Suppl5):S2–S10.PubMedGoogle Scholar
  122. 122.
    Rogers LR, Morris HH, Lupica K. Effect of cranial irradiation on seizure frequency in adults with low-grade astrocytoma and medically intractable epilepsy. Neurology 1993;43:1599–1601.PubMedGoogle Scholar
  123. 123.
    Regis Y, Roberts DW. Gamma knife radiosurgery relative to microsurgery: epilepsy. Stereotact Funct Neurosurg 1999;72 Suppl 1:11–21.PubMedGoogle Scholar
  124. 124.
    Warnke PC, Berlis A, Weyerbrock A et al. Significant reduction of seizure incidence and increase of benzodiazepine receptor density after interstitial radiosurgery in low-grade gliomas. Acta Neurochir Suppl (Wien) 1997;68:90–92.Google Scholar
  125. 125.
    Schiller Y, Cascino GD, So EL et al. Discontinuation of antiepileptic drugs after successful epilepsy surgery. Neurology 2000 54:346–349.PubMedGoogle Scholar
  126. 126.
    Khajavi K, Comair YG, Wyllie E et al.. Surgical management of pediatric tumor-associated epilepsy. J Child Neurol 1999;14:15–25.PubMedGoogle Scholar
  127. 127.
    Salanova V, Markand O, Worth R. Longitudinal follow-up in 145 patients with medically refractory temporal lobe epilepsy treated surgically between 1984 and 1995. Epilepsia 1999;40:1417–23.Google Scholar
  128. 128.
    Eliashiv SD, Dewar S, Wainwright I et al. Long–term follow-up after temporal lobe resection for lesions associated with chronic seizures. Neurology 1997;48:1383–1388.PubMedGoogle Scholar
  129. 129.
    Zentner J, Hufnagel A, Wolf HK et al. Surgical treatment of neoplasms associated with medically intractable epilepsy. Neurosurgery 1997;41:378–386.PubMedGoogle Scholar
  130. 130.
    Britton JW, Cascino GD, Sharbrough FW et al. Low-grade glial neoplasms and intractable partial epilepsy: efficacy of surgical treatment. Epilepsia 1994;35:1130–1135.PubMedGoogle Scholar
  131. 131.
    Kirkpatrick PJ, Honavar M, Janota I et al. Control of temporal lobe epilepsy following en bloc resection of low-grade tumors. J Neurosurg 1993;78:19–25.PubMedGoogle Scholar
  132. 132.
    Cascino GD, Kelly PJ, Hirschorn KA, et al. Stereotactic resection of intra-axial cerebral lesions in partial epilepsy. Mayo Clin Proc 1990;65:1053–1060.PubMedGoogle Scholar
  133. 133.
    Khan RB, Boop FA, Onar A et al. Seizures in children with low-grade tumors: outcome after tumor resection and risk factors for uncontrolled seizures. J Neurosurg 2006;104(6 Suppl Pediatrics):377–382.PubMedGoogle Scholar
  134. 134.
    Spencer DD, Spencer SS, Mattson RH et al. Intracerebral masses in patients with intractable partial epilepsy. Neurology 1984;34:432–436.PubMedGoogle Scholar
  135. 135.
    Awad IA, Rosenfeld J, Ahl J et al. Intractable epilepsy and structural lesions of the brain: mapping, resection strategies, and seizure outcome. Epilepsia 1991;32:179–186.PubMedGoogle Scholar
  136. 136.
    Lieu AS, Howng SL. Intracranial meningiomas and epilepsy: incidence, prognosis and influencing factors. Epilepsy Res. 2000;38:45–52.PubMedGoogle Scholar
  137. 137.
    Chozick BS, Reinert SE, Greenblatt SH. Incidence of seizures after surgery for supratentorial meningiomas: a modern analysis. J Neurosurg 1996;84:382–386.PubMedGoogle Scholar
  138. 138.
    Berger MS, Ghatan S, Haglund MM et al. Low-grade gliomas associated with intractable epilepsy: seizure outcome utilizing electrocorticography during tumor resection. J Neurosurg 1993;79:62–69.PubMedGoogle Scholar
  139. 139.
    Hagland MM, Berger MS, Kunkel DD et al. Changes in gamma-aminobutyric acid and somatostatin in epileptic cortex associated with low-grade gliomas. J Neurosurg 1992;77:209–216.Google Scholar
  140. 140.
    Strowbridge BW, Bean AJ, Spencer DD et al.. Low levels of somatostatin-like immunoreactivity in neocortex resected from presumed seizure foci in epileptic patients. Brain Res 1992;587:164–168.PubMedGoogle Scholar
  141. 141.
    Bateman DE, Hardy JA, McDermott JR et al. Amino acid neurotransmitter levels in gliomas and their relationship to the incidence of epilepsy. Neurol Res 1988;10:112–114.PubMedGoogle Scholar
  142. 142.
    Berger MS. Functional mapping–guided resection of low-grade gliomas. Clin Neurosurg 1995;42:437–452.PubMedGoogle Scholar
  143. 143.
    Kirkpatrick PJ, Honavar M, Janota I et al. Control of temporal lobe epilepsy following en bloc resection of low-grade tumors. J Neurosurg 1993;78:19–25.PubMedGoogle Scholar
  144. 144.
    Pilcher WH, Silbergeld DL, Berger MS et al.. Intraoperative electrocorticography during tumor resection: impact on seizure outcome in patients with gangliogliomas. J Neurosurg 1993 Jun;78(6):891–902.Google Scholar
  145. 145.
    Berger MS, Ghatan S, Geyer JR et al.. Seizure outcome in children with hemispheric tumors and associated intractable epilepsy: the role of tumor removal combined with seizure foci resection. Pediatr Neurosurg 1991–92;17:185–191.Google Scholar
  146. 146.
    Schaller B, Ruegg SJ. Brain tumor and seizures: pathophysiology and its implication for treatment revisited [published retraction appears in Epilepsia 44:1463, 2003]. Epilepsia 44:1223–1232, 2003.PubMedGoogle Scholar
  147. 147.
    Whittle IR, Beaumont A. Seizures in patients with supratentorial oligodendroglial tumours.: clinicopathological features and management considerations. Acta Neurochir 1995;135:19–24.Google Scholar
  148. 148.
    Smith DF, Hutton JL, Sandermann D, et al. The prognosis of primary intracerebral tumours presenting with epilepsy: the outcome of medical and surgical management. J Neurol Neurosurg Psychiatry 1991;54:915–920.PubMedGoogle Scholar
  149. 149.
    MRC Brain Tumour Working Party. Prognostic factors for high-grade malignant gliomas: development of a prognostic index. J Neurooncol 1990;9:47–55.Google Scholar
  150. 150.
    Scott GM, Gibberd FB. Epilepsy and other factors in the prognosis of gliomas. Acta Neurol Scand 1980;61:227–239.PubMedGoogle Scholar
  151. 151.
    Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neurology 2000;54:1886–1893.PubMedGoogle Scholar
  152. 152.
    Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 42:515–524, 2001.PubMedGoogle Scholar
  153. 153.
    Mauro AM, Bomprezzi C, Morresi S et al. Prevention of early post-operative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. J Neurooncol 2007;81:279–285.PubMedGoogle Scholar
  154. 154.
    Kuijlen JMA, Teernstra OPM, Kessels AGH, et al. Effectiveness of antiepileptic prophylaxis used with supratentorial craniotomies: a meta-analysis. Seizure 1996;5:291–298.PubMedGoogle Scholar
  155. 155.
    Siomin V, Angelov L, Li L et al.. Results of a survey of neurosurgical practice patterns regarding the prophylactic use of anti-epilepsy drugs in patients with brain tumors. J Neurooncol 74:211–215, 2005.PubMedGoogle Scholar
  156. 156.
    Mehta MP, Rodrigus P, Terhaard CH et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003;21:2529–2536.PubMedGoogle Scholar
  157. 157.
    Dalmau J, Tuzun E, Wu H-y et al. Paraneoplastic anti-N-methyl-d-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36.Google Scholar
  158. 158.
    Garg RK. Posterior leukoencephalopathy syndrome. Postgrad Med J 2001;77:24–28.PubMedGoogle Scholar

Copyright information

© Humana Press, Totowa, NJ 2008

Authors and Affiliations

  • Michael J. Glantz
  • Julia Batten

There are no affiliations available

Personalised recommendations